Longitudinal Population-based Observational Study of COVID-19 in the UK Population (COVIDENCE UK)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04330599 |
Recruitment Status :
Active, not recruiting
First Posted : April 1, 2020
Last Update Posted : January 31, 2022
|
Sponsor:
Queen Mary University of London
Collaborators:
King's College London
London School of Hygiene and Tropical Medicine
University of Edinburgh
Swansea University
Queen's University, Belfast
Barts & The London NHS Trust
Information provided by (Responsible Party):
Queen Mary University of London
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | March 31, 2020 | ||||
First Posted Date | April 1, 2020 | ||||
Last Update Posted Date | January 31, 2022 | ||||
Actual Study Start Date | May 1, 2020 | ||||
Estimated Primary Completion Date | April 1, 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Incidence of confirmed COVID-19 [ Time Frame: 5 years ] | ||||
Original Primary Outcome Measures |
Incidence of suspected, probable or confirmed COVID-19 [ Time Frame: 5 years ] | ||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Longitudinal Population-based Observational Study of COVID-19 in the UK Population | ||||
Official Title | Longitudinal Population-based Observational Study of COVID-19 in the UK Population | ||||
Brief Summary | COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:
|
||||
Detailed Description | Not Provided | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Retention: Samples Without DNA Description: Eluates from dried blood spots
|
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | UK residents aged 16 years or more | ||||
Condition | COVID-19 | ||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * | Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, Young KS, Davies MR, Thompson KN, Ashman J, Rajpoot SS, Kayyale AA, El Rifai S, Lloyd PJ, Jolliffe D, Timmis O, Finer S, Iliodromiti S, Miners A, Hopkinson NS, Alam B, Lloyd-Jones G, Dietrich T, Chapple I, Pfeffer PE, McCoy D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Breen G, Shaheen SO, Martineau AR. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax. 2021 Nov 30. pii: thoraxjnl-2021-217487. doi: 10.1136/thoraxjnl-2021-217487. [Epub ahead of print] | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Active, not recruiting | ||||
Actual Enrollment |
13000 | ||||
Original Estimated Enrollment |
12000 | ||||
Estimated Study Completion Date | April 1, 2025 | ||||
Estimated Primary Completion Date | April 1, 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: none |
||||
Sex/Gender |
|
||||
Ages | 16 Years and older (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | United Kingdom | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04330599 | ||||
Other Study ID Numbers | COVIDENCE UK | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Current Responsible Party | Queen Mary University of London | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor | Queen Mary University of London | ||||
Original Study Sponsor | Same as current | ||||
Collaborators |
|
||||
Investigators | Not Provided | ||||
PRS Account | Queen Mary University of London | ||||
Verification Date | January 2022 |